Romidepsin: a novel histone deacetylase inhibitor for cancer
- 24 June 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 20 (8), 1151-1158
- https://doi.org/10.1517/13543784.2011.594437
Abstract
(2011). Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opinion on Investigational Drugs: Vol. 20, No. 8, pp. 1151-1158. doi: 10.1517/13543784.2011.594437Keywords
This publication has 49 references indexed in Scilit:
- Nonhistone protein acetylation as cancer therapy targetsExpert Review of Anticancer Therapy, 2010
- Histone Deacetylase Inhibitors in Cancer TherapyJournal of Clinical Oncology, 2009
- Histone deacetylase inhibitors: Potential in cancer therapyJournal of Cellular Biochemistry, 2009
- Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsinMolecular Cancer Therapeutics, 2008
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone CodeAnnals of the New York Academy of Sciences, 2003
- Regulation and Destabilization of HIF-1α by ARD1-Mediated AcetylationCell, 2002
- Histone AcetyltransferasesAnnual Review of Biochemistry, 2001
- Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genesNature Medicine, 2001
- The Human Histone Deacetylase FamilyExperimental Cell Research, 2001